成人国产精品一级毛片视频,毛片三级在线观看,中国黄色在线观看,婷婷久久综合九色综合九七,久久久免费视频观看,国产99在线播放,日本成人福利

產(chǎn)品分類導(dǎo)航
2025制藥工業(yè)深圳展
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes
Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes

Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes

更新時(shí)間:2025-06-20

價(jià)格:  元/個(gè)
CAS號(hào): 2023788-19-2
藥典: 中國(guó)藥典,企業(yè)標(biāo)準(zhǔn)
級(jí)別: injection
立即詢盤
收藏
產(chǎn)品詳情
產(chǎn)品關(guān)鍵詞: Dual-Action Agonist,Type 2 Diabetes Treatment,Weight Management,Once-Weekly Dosing,GIP/GLP-1 Receptor Activation
是否為生產(chǎn)商:
產(chǎn)品包裝規(guī)格: 5mg/Ampoule 10mg/Ampoule 15mg/Ampoule 20mg/Ampoule 30mg/Ampoule 10Ampoules/Box
主要銷售市場(chǎng): 中國(guó),北美洲,中/南美洲,西歐,東歐,大洋洲,亞洲,中東,非洲
產(chǎn)品描述:






Mechanism of Action(作用機(jī)理)

Tirzepatide is a dual-agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It mimics the actions of these two incretin hormones to enhance glucose homeostasis and appetite regulation:

  1. GIP Receptor Activation: Tirzepatide binds to the GIP receptor, stimulating insulin secretion in a glucose-dependent manner, which helps lower blood glucose levels. It also promotes the clearance of dietary triglycerides and enhances lipid metabolism in adipose tissue.
  2. GLP-1 Receptor Activation: It activates the GLP-1 receptor, leading to additional insulin secretion, suppression of glucagon release, and slowing of gastric emptying. This interaction also reduces appetite and food intake by acting on the central nervous system.
  3. Synergistic Effects: By activating both receptors simultaneously, tirzepatide provides a more potent and comprehensive effect on glucose control and weight management compared to single-agonist therapies.

Applications(應(yīng)用)

  1. Type 2 Diabetes Management: Tirzepatide is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
  2. Weight Management: It is also indicated for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity. Clinical trials have shown significant weight loss benefits.
  3. Other Potential Uses: Ongoing studies are exploring its potential in non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea (OSA), and chronic kidney disease (CKD).

Dosage Instructions(用法用量)

  1. Initial Dose: The recommended starting dose is 2.5 mg once weekly.
  2. Titration: The dose can be increased to 5 mg, 7.5 mg, or 10 mg once weekly, depending on the patient's glycemic response and tolerability.
  3. Injection Instructions: Tirzepatide is administered subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.
  4. Missed Dose: If a dose is missed, administer as soon as possible within 3 days. If more than 3 days have passed, skip the missed dose and resume the regular schedule.

Storage(保存)

  1. Unopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.
  2. Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.
  3. Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.


上海浦津林州制藥有限公司
注冊(cè)資本
聯(lián)系人
聯(lián)系電話
查看聯(lián)系方式
快速詢盤
詢盤主題
請(qǐng)輸入詢盤主題
詢盤信息
請(qǐng)輸入詢盤信息
滑動(dòng)驗(yàn)證
請(qǐng)完成滑塊驗(yàn)證
快速發(fā)送詢盤
CPHI制藥在線為您找到Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes 價(jià)格、Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes 詳細(xì)參數(shù)、Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes 相關(guān)產(chǎn)品、Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes 供應(yīng)商等信息,想了解當(dāng)前Tirzepatide: Innovative Dual-Action Therapy for Type 2 Diabetes 最新報(bào)價(jià),請(qǐng)聯(lián)系上海浦津林州制藥有限公司。
2006-2025 上海博華國(guó)際展覽有限公司版權(quán)所有(保留一切權(quán)利) 滬ICP備05034851號(hào)-57
西充县| 宜都市| 神农架林区| 永兴县| 同仁县| 黑龙江省| 封开县| 宁明县| 吉水县| 开封县| 张家港市| 东至县| 浦县| 金门县| 南京市| 水城县| 惠安县| 渭南市| 固镇县| 城固县| 阿城市| 淮南市| 郓城县| 江孜县| 沽源县| 蒙城县| 蕲春县| 德阳市| 佛坪县| 和田市| 哈尔滨市| 南丰县| 化州市| 景洪市| 岚皋县| 中江县| 大洼县| 抚顺市| 缙云县| 南通市| 桦南县|